OncoMatch/Clinical Trials/NCT06970743
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Is NCT06970743 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including BGB-16673 and Bendamustine for chronic lymphocytic leukemia.
Treatment: BGB-16673 · Bendamustine · Rituximab · Methylprednisolone — The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab) in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to covalent Bruton tyrosine kinase inhibitor(s) (cBTKi).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: Bruton tyrosine kinase inhibitor
Previously received treatment for CLL/SLL with a covalent BTKi
Cannot have received: autologous stem cell transplant
Exception: unless ≥ 3 months after transplant
Prior autologous stem cell transplant (unless ≥ 3 months after transplant)
Cannot have received: CAR-T cell therapy
Exception: unless ≥ 6 months after cell infusion
chimeric antigen receptor-T cell (unless ≥ 6 months after cell infusion)
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate kidney function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06970743 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous stem cell transplant, CAR-T cell therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages